<DOC>
	<DOCNO>NCT01935102</DOCNO>
	<brief_summary>Although many attempt do identify vascular endothelial growth factor-A ( VEGF-A ) single nucleotide polymorphism ( SNPs ) correlate bevacizumab response , advanced cancer patient , result still inconclusive . We conduct pharmacogenetic study ass , population metastatic breast cancer ( MBC ) patient , possible predictive role VEGF-A , VEGF receptor-2 ( VEGFR-2 ) , interleukin-8 ( IL-8 ) , hypoxia inducible factor-1α ( HIF-1α ) , hypoxia inducible factor-2α ( HIF-2α ) thrombospondin-1 ( TSP-1 ) SNPs bevacizumab response combine first-line paclitaxel progression free survival ( PFS ) . Analyses perform germline DNA obtain blood sample SNPs investigate real-time polymerase chain reaction ( PCR ) technique . The multifactor dimensionality reduction ( MDR ) methodology apply investigate interaction SNPs .</brief_summary>
	<brief_title>Polymorphism Interaction Predict Bevacizumab Efficacy</brief_title>
	<detailed_description>Metastatic breast cancer ( MBC ) patient eight Italian division Medical Oncology , histologically confirm HER2-negative MBC , treat first-line therapy include bevacizumab 10 mg/m2 i.v . day 1 15 combine first-line paclitaxel 90 mg/m2 i.v . day 1 , 8 15 , every 4 week , enrol present pharmacogenetic study . MBC patient treat first-line chemotherapy include paclitaxel without bevacizumab also enrol control group . Sites metastatic disease radiologically re-evaluated accord Response Evaluation Criteria Solid Tumors ( RECIST ) criteria 1.1 , patient measurable disease . In patient without measurable lesion , progression disease define new lesion appear exist lesion evolve . Likewise , case non measurable lesion , deterioration clinical condition due treatment toxicity , define progression disease . Progression-free survival ( PFS ) define period time begin treatment first observation disease progression describe , death cause . All patient assess response , PFS overall survival . Each patient enter study sign inform consent . The protocol approve ethic committee Azienda Ospedaliera-Universitaria Pisana , Pisa , Italy , ( CESM 3077/2010 ) . Genotyping analysis Blood sample ( 3 ml ) collect ethylenediaminetetraacetic acid ( EDTA ) tube stored -80°C . Genes polymorphism involve angiogenesis pathway already suggest predictor bevacizumab response , choose present analysis . Germline DNA extraction perform use QIAamp DNA Blood Mini Kit ( Qiagen , Valencia , California , USA ) . Allelic discrimination gene perform use ABI PRISM 7900 SDS instrument ( Applied Biosystems , Carlsbad , California , USA ) validate TaqMan® SNP genotyping assay ( Applied Biosystems ) . PCR reaction carry accord manufacturer 's protocol . Genotyping performed adequate number event ( &gt; 80 % study population ) report term PFS . Statistical analysis The first aim retrospective analysis evaluate possible role investigate gene polymorphism predict bevacizumab response term PFS . The secondary end-points correlation overall survival ( OS ) response rate . All polymorphism analyze deviation Hardy-Weinberg Equilibrium ( HWE ) mean comparison observe allelic distribution expect HWE χ2 test . Any correlation gene polymorphisms response rate analyze two-sided Fisher 's Exact Test . The association individual polymorphism relevant clinical-pathological characteristic PFS test use Cox proportional hazard model . The Multifactor Dimensionality Reduction ( MDR ) methodology apply ( use version 2.0 beta 6 MDR software available http : //sourceforge.net/projects/mdr/ ) investigate role interaction gene polymorphism identify biomarkers paclitaxel plus bevacizumab response . The genotype combination high PFS benefit correlate OS improvement chosen analysis . The difference PFS favourable genetic profile unfavourable genetic profile assess log-rank test Kaplan-Meier method evaluate survival curve . A Cox proportional hazard model , possible genetic profile clinical pathological patient characteristic individually correlate PFS , use calculate adjust hazard ratio ( HR ) 95 % confidence interval ( 95 % CI ) . A P value &lt; 0.05 accept statistically significant . The Kaplan-Meier Cox proportional hazard analysis perform use SPSS version 17.0 ( SPSS , Chicago , IL ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>diagnosis histologically confirm metastatic breast cancer age ( 18 90 year ) Eastern Cooperative Oncology Group ( ECOG ) performance status ( 0 12 ) hormonalreceptor status ( positive negative ) previous adjuvant chemotherapy ( none , anthracycline anthracycline plus taxane ) previous hormonal therapy ( adjuvant metastatic ) diseasefree interval first diagnosis breast cancer ( ≤ &gt; 12 month ) extent disease ( ≤ &gt; 3 site ) location disease ( viscera bone ) disease evaluation ( measurable nonmeasurable ) bevacizumab maintenance ( yes ) . Patients human epidermal growth factor receptor type 2 ( HER2 ) positive</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>single nucleotide polymorphism</keyword>
	<keyword>VEGF-A</keyword>
	<keyword>VEGFR-2</keyword>
	<keyword>IL-8</keyword>
</DOC>